Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies
Press Releases

Enovis Appoints Tim Czartoski as President, U.S. Surgical and Global Product and Enabling Technologies

WILMINGTON, DE, Sept. 09, 2024 (GLOBE NEWSWIRE) — Enovis™ (NYSE: ENOV), an innovation-driven medical technology growth company, is pleased to announce the appointment of Tim Czartoski to the position of President, U.S. Surgical and Global Product and Enabling Technologies. Mr. Czartoski has direct responsibility for the Company’s U.S. Surgical business, including the global surgical product engine and enabling technologies. He reports to Louie Vogt, Group President of Enovis’ Reconstructive (Recon) Business Group.

Mr. Czartoski is a successful MedTech executive with over 22 years of experience at Depuy Synthes, the Orthopaedics Company of Johnson & Johnson, where he progressed in leadership roles of increasing responsibility. In his most recent role as President of Depuy Synthes, U.S., Mr. Czartoski led the Company’s joint reconstruction, trauma, spine, digital technology, capital, sports and CMF businesses. He also served as the Worldwide President of Joint Reconstruction and Power Tools. 

Mr. Czartoski has a B.S. from Ohio State University, an M.S. from Columbia in Technology Management and an MBA from Notre Dame.

“Tim is a highly accomplished orthopedic leader with an incredible track record of delivering strategic and commercial excellence,” said Mr. Vogt. “I’m confident that his experience and leadership will accelerate Enovis’ growth potential and strengthen our surgical pipeline around the world.”


About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.



Media Contact
Katie Sweet, Vice President, Corporate Communications
Enovis
Katie.Sweet@enovis.com

Related Articles
TipRanks Auto-Generated NewsdeskEnovis Corporation Reports Strong Sales Growth in Q3 2024
TheFlyMorning Movers: CVS Health surges and ODP sinks following Q3 results
TheFlyEnovis raises FY24 adjusted EPS view to $2.75-$2.80 from $2.62-$2.77
Go Ad-Free with Our App